This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Medulloblastoma
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States, 94304
Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States, 32806
St. Joseph's Children's Hospital, Tampa, Florida, United States, 33607
C.S. MOTT Children's Hospital, University of Michigan, Ann Arbor, Michigan, United States, 48109
Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States, 55404
St. Jude Children's Research Hospital, Memphis, Tennessee, United States, 38105
UT Southwestern/Simmons Cancer Center, Dallas, Texas, United States, 75235
Cook Children's Medical Center, Fort Worth, Texas, United States, 76104
Texas Children's Hospital, Houston, Texas, United States, 77477
Primary Children's Hospital, Salt Lake City, Utah, United States, 84113
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to 59 Months
ALL
No
St. Jude Children's Research Hospital,
Giles W. Robinson, MD, PRINCIPAL_INVESTIGATOR, St. Jude Children's Research Hospital
Aditi Bagchi, MD, PhD, PRINCIPAL_INVESTIGATOR, St. Jude Children's Research Hospital
2035-07